Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2026 21:18 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC

NEOTORCH has finished its final analysis and met all the primary endpoints of EFS and MPR rate in the stage Ⅱ-Ⅲ NSCLC patients.